Hairy cell leukemia is an uncommon malignancy of hematopoietic stem cells, named for the fine, hair-like projections that cover the surface of the malignant cells. It predominantly affects men and is driven in nearly all cases by a single acquired mutation, BRAF V600E, which was identified more than a decade ago and has since become both a diagnostic marker and a therapeutic target. The disease has a remarkable treatment history: described first in 1923, it was initially managed with splenectomy, then advanced through interferon and the purine analog pentostatin before cladribine, a nucleoside analog that is toxic to lymphocytes, became the backbone of therapy. More recently, combinations of cladribine with the monoclonal antibody rituximab have pushed remission rates even higher, and BRAF inhibitors such as vemurafenib have shown excellent results in refractory cases. Yet for all these advances, the standard cladribine schedule, a continuous infusion given on five to seven consecutive days, has remained essentially unchanged for two decades.

That constancy has persisted despite a persistent problem: toxicity. Cladribine profoundly depletes normal white blood cells, particularly neutrophils, leaving patients vulnerable to serious bacterial infections. Many require hospitalization, intravenous antibiotics, growth factor support, and blood product transfusions during the weeks following treatment. The concern became acute roughly fifteen years ago when deaths occurred among patients receiving continuous cladribine infusions. This prompted a handful of investigators to ask whether the same drug, delivered as one weekly outpatient infusion instead of daily doses, might achieve comparable disease control with far less collateral damage. The idea has biological logic: cladribine is a long-acting drug that accumulates in lymphocytes, and stretching its delivery across weeks may moderate the depth and duration of immunosuppression without compromising the lethal effect on malignant cells. Prior studies comparing the two schedules, including two prospective randomized trials from European groups, produced mixed results, with some finding no significant difference in efficacy and others reporting fewer neutropenic and infectious complications with weekly dosing.

The new study, led by Jacqueline A. Turner and colleagues including William A. Robinson, adds substantially to this literature by combining treatment response data with long-term survival analysis and modern molecular monitoring. The researchers identified 36 treatment-naïve patients with hairy cell leukemia treated at their institution since 2002. Eighteen received intermittent cladribine, meaning one infusion per week for 5 to 7 weeks, while 18 received the standard continuous schedule of daily outpatient infusions over 5 to 7 days. The groups were broadly similar at baseline: 83.3 percent of patients in each group were male, and initial white blood cell counts, hemoglobin concentrations, and platelet counts were statistically indistinguishable. The median age at diagnosis differed notably, at 58 years in the weekly-dosing group versus 45 years in the continuous group, a disparity the authors acknowledge may reflect shifting referral patterns over the two-decade study window.

The efficacy results favored weekly dosing on every clinically meaningful measure tested. Beyond the difference in complete remission rates, 94.4 percent versus 61.1 percent, no patient in the weekly group experienced progressive disease, while 38.9 percent of the continuous-infusion group did. Kaplan-Meier analysis showed no difference in overall survival between the groups, a finding the authors attribute to the effectiveness of salvage therapies at relapse, but progression-free survival differed profoundly, with a p-value below 0.0001 by log-rank testing. Hospitalizations during treatment induction were less frequent with weekly dosing, affecting 4 of 18 patients compared with 6 of 18, and among three patients in the study who had relapsed after continuous cladribine and were later re-challenged with the weekly schedule, all achieved complete responses, with two remaining in remission for years and none requiring hospitalization during the weekly regimen, in contrast to hospitalizations and neutropenic fevers that had complicated their original continuous-infusion treatment.

Toxicity data painted a more nuanced picture. Neutropenia was nearly universal in both groups, affecting 88.9 percent of weekly-dosing patients and 92.9 percent of continuous-infusion patients with recorded data, and neutropenic fever occurred in roughly 43 to 44 percent of both groups. Antibiotic use was identical at 50 percent, and the proportion of patients requiring growth factor support or blood product transfusions was also comparable. This raises an important interpretive question, because the weekly group was far more likely to have received rituximab after cladribine, 72.2 percent versus 27.2 percent, a chemoimmunotherapy addition that has itself been shown to deepen remissions and extend survival. The authors are candid about this limitation, noting that the non-randomized design and the imbalance in rituximab exposure may have contributed to the observed differences and preclude definitive conclusions about which element of the regimen drives the benefit.

The study also offers a window into the future of disease monitoring in hairy cell leukemia. In a subset of more recently treated patients, the team used quantitative polymerase chain reaction on peripheral blood samples to track the frequency of the mutant BRAF V600E allele, essentially using the driver mutation itself as a measurable residual disease marker. At five years after treatment, all tested patients in both groups had undetectably low levels of the mutant allele, and the decline in mutant allele burden correlated closely with clinical remission. Because the assay requires only a blood draw, the authors argue it could serve as a less invasive alternative to the repeated bone marrow biopsies traditionally used to assess remission depth, and they recommend that serial BRAF mutant allele frequency testing be incorporated into routine care. The feasibility of monitoring relapse through a simple blood test is particularly attractive in a disease whose treatment is most effective when started early.

The rarity of hairy cell leukemia complicates the path forward. With only a few thousand new cases diagnosed annually in the United States, prospective randomized trials comparing the two schedules are difficult to mount and slow to accrue, which helps explain why the question has lingered for decades with only mixed and limited answers. The two previously conducted randomized trials, from the Polish Adult Leukemia Group and the Swiss Group for Clinical Cancer Research, found no significant efficacy differences, while earlier Italian work by Lauria and colleagues and by Zinzani and colleagues reported that weekly administration reduced infectious complications. The Colorado experience, with its extended follow-up and favorable progression-free survival signal, tilts the accumulated evidence somewhat further toward the weekly schedule, though the authors concede that confirmation in larger, prospective, ideally multi-institutional cohorts would be valuable and have committed to continuing to expand and update their own series.

For patients, the practical implications are appealing regardless of which component of the regimen proves decisive. A once-weekly outpatient infusion eliminates the logistical burden of consecutive daily hospital visits, and the reduced hospitalization rate translates into fewer exposures to drug-resistant hospital pathogens for an already immunocompromised population. Because most hairy cell leukemia patients are older and carry comorbidities, the authors emphasize that an ideal regimen must be both effective and low-risk across short- and long-term horizons, criteria they argue weekly cladribine followed by rituximab appears to meet. Their conclusion is measured but hopeful: the weekly schedule represents a feasible strategy supported by institutional experience, and while randomized validation would be ideal, the totality of the data, higher complete remission rates, superior progression-free survival, comparable overall survival and toxicity, and fewer hospitalizations, suggests a genuine clinical benefit that the field should not ignore.

The study arrives at a moment when the treatment of hairy cell leukemia is already undergoing a molecular renaissance, driven by the discovery that a single point mutation powers the disease and by the growing clinical repertoire of BRAF inhibitors and antibody combinations. Against that backdrop, the Colorado findings are a reminder that sometimes meaningful progress in oncology comes not from new molecules but from new ways of using old ones. Cladribine has been a mainstay of hairy cell leukemia therapy since the early 1990s, and if simply rearranging its administration calendar can keep more patients in durable remission with fewer trips to the hospital, the change would cost essentially nothing to implement. Whether weekly cladribine followed by rituximab formally becomes the new standard will depend on the larger studies the authors call for, but for a disease that has long been a treatment success story, this work proposes a way to make the story even better.

This new study, led by Dr. Antonio Jimenez Jimenez of the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, systematically explores the efficacy of using partially matched unrelated donors combined with novel GVHD prophylaxis regimens. By employing post-transplant cyclophosphamide—an immune-suppressing chemotherapy traditionally used in marrow transplants—to mitigate GVHD risk, researchers have expanded the feasible donor pool without compromising patient outcomes. Results from the phase 2, nonrandomized clinical trial reveal that one-year survival rates and rates of moderate to severe chronic GVHD in recipients of 6/8 or 7/8 matched donors parallel those in patients receiving fully matched grafts.

Hemopoietic cell transplantation remains a potentially curative therapy for various hematologic malignancies including leukemia, lymphoma, and myelodysplastic syndromes. Despite its curative potential, the procedure’s success has depended heavily on the presence of an HLA-matched donor, limiting treatment accessibility for many patients. Given that approximately 25% of patients with siblings may find a full match within their family, and considering the National Marrow Donor Program (NMDP) registry’s over 42 million donors worldwide, the barriers remain formidable, especially for racial and ethnic minorities. This new evidence fundamentally challenges pre-existing paradigms by suggesting that partial matches, under appropriate immune modulation, can suffice to yield favorable transplant outcomes.

Cyclophosphamide’s role in post-transplant care has evolved remarkably. Historically administered pre-transplant as a conditioning agent, its application several days post-transplant capitalizes on its selective ability to eliminate alloreactive T cells responsible for GVHD, while sparing regulatory and hematopoietic progenitor cells. This immunomodulatory property allows for greater tolerance of mismatched HLA antigens, effectively balancing graft-versus-leukemia effects with GVHD risk. The study harnessed this mechanism in combination with additional immune suppressants, employing either reduced-intensity conditioning (RIC), nonmyeloablative conditioning (NMA), or myeloablative conditioning (MAC) to optimize outcomes across patient populations of varying clinical fitness levels.

The trial enrolled 145 adult patients who lacked matched donors and underwent peripheral blood stem cell transplantation sourced through the NMDP. The shift from bone marrow to peripheral blood stem cells as a graft source has been increasingly prevalent, offering advantages such as more rapid engraftment and immune reconstitution. Strikingly, the majority of donors were HLA-matched at only 6/8 or 7/8 loci, yet patients experienced robust one-year survival rates, specifically 78.6% in the RIC/NMA subgroup and 83.8% in those conditioned with MAC. Concurrently, incidences of moderate-to-severe chronic GVHD were impressively low, underscoring the regimen’s high tolerability and safety.

An important aspect of the findings is that patients with lower HLA match levels did not experience inferior outcomes compared to those with higher match degrees. This parity in clinical endpoints not only supports implementation in clinical practice but also signals a paradigm shift—transplant physicians can now prioritize donor attributes beyond HLA compatibility, including donor availability, age, and cytomegalovirus serostatus. Expanding the donor pool through permissive mismatches where appropriate reduces wait times, allowing more patients timely access to potentially curative transplantation.

This trial, conducted through a highly collaborative network involving 21 centers under the sponsorship of the NMDP and the Center for International Blood and Marrow Transplant Research (CIBMTR), underscores the power of cooperative clinical research efforts. The NMDP’s extensive registry infrastructure facilitates rapid identification and procurement of grafts from international donors, bridging geographic and demographic gaps in donor candidacy. The study’s results echo smaller prior investigations and align with evidence demonstrating the efficacy of post-transplant cyclophosphamide in related donor settings, further reinforcing its broad applicability.

From a mechanistic standpoint, the study elucidates how cyclophosphamide’s timing and dose calibrate immune balance. Administered post-transplant, it targets rapidly proliferating alloreactive T cells responsible for acute and chronic GVHD without abolishing the beneficial graft-versus-leukemia effect crucial for eradicating malignant cells. Additionally, combining it with other immunosuppressive agents and varied conditioning intensities accommodates patient heterogeneity, especially important for older or more medically frail individuals who may not tolerate myeloablative regimens.

Looking beyond immediate transplantation outcomes, the research team continues to longitudinally evaluate longer-term survival, relapse rates, and late-onset complications among this patient cohort. Furthermore, ongoing trials are investigating lower cyclophosphamide dosing schedules aimed at reducing infection risks, a known complication of immunosuppression, and exploring alternative drug combinations to optimize GVHD prophylaxis further. Pediatric cohorts are also being assessed, promising to broaden applicability across the age spectrum.

This work also addresses a critical health equity concern. While patients from well-represented ethnic populations have approximately a 70% probability of finding a full donor match in registries, those from underrepresented minorities face markedly diminished chances. By expanding permissible mismatches with effective GVHD prevention, this protocol offers hope for reducing disparities in access to life-saving transplantation therapies, a historic challenge in hematologic oncology.

Dr. Jimenez Jimenez emphasizes the necessity of this innovation, calling the trial a response to an urgent clinical need. The study exemplifies translational research where scientific discovery directly informs patient care protocols, expanding not only the donor pool but also the therapeutic options for complex, high-risk patients. The global recognition garnered by Sylvester’s transplant program further highlights their leadership role in pioneering these advancements.

In summary, this pivotal study recalibrates the boundaries of donor compatibility in hematopoietic stem cell transplantation, demonstrating that partial HLA matches combined with the strategic use of post-transplant cyclophosphamide can achieve outcomes previously thought exclusive to fully matched grafts. For patients with blood cancers, this research translates to increased access to potentially curative transplants, reduced waiting times, and personalized donor selection strategies, marking a major milestone in the evolution of hematopoietic transplantation medicine.

Subject of Research: Hematopoietic stem cell transplantation using partially HLA-matched unrelated donors with post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis.

Article Title: Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

News Publication Date: June 26, 2025

Web References:

• https://ascopubs.org/doi/10.1200/JCO-25-00856
• https://clinicaltrials.gov/study/NCT04904588
• http://nmdp.org/
• https://umiamihealth.org/en/sylvester-comprehensive-cancer-center

References: Available within the Journal of Clinical Oncology article.

Image Credits: Photo by Sylvester Cancer Center

Keywords: Hematology, Transplantation, Blood diseases, Blood cancer, Tissue transplantation, Bone marrow transplantation